Clinical Trial Update: Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the molecular imaging agent [123I]I-DARPIN-Ec1 targeting EpCAM receptors in lung cancer and ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Ovarian Cancer

Drugs mentioned

• [123I]I-DARPIN-Ec1 (iodine-123 labeled DARPIN Ec1)

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Lung Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED